Apnimed (APMD) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apnimed is the larger company by market cap ($669.8 million vs $666.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | NVCT |
|---|---|---|
| Share price | $16.09 | $19.39 |
| Market cap | $669.84M | $666.80M |
| 1-day change | -6.70% | -2.27% |
| YTD return | — | +156.82% |
| 1-year return | — | +218.91% |
| P/E ratio (TTM) | 1.21 | — |
| EPS (TTM) | $13.34 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-26.44M |
| 52-week high | $35.29 | $29.28 |
| 52-week low | $13.88 | $5.77 |
| Distance from 52-week high | -54.41% | -33.77% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +210.75% | +82.57% |
| Average volume | 458.58K | 206.37K |
| Shares outstanding | 41.63M | 34.39M |
| Employees | 112 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
APMD vs NVCT FAQ
Which is bigger, Apnimed or Nuvectis Pharma?
Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $666.80M for Nuvectis Pharma (NVCT).
Are Apnimed and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.